GVHD Pathophysiology

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.

In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.

CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.

The FDA's Expedited Investigational New Drug (IND) Pilot Program pairs trial sponsors and research institutions to promote phase 1 trials in the US.

During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.

FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.

Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.